1339003-34-7

Basic information

• Product Name: 2-phenyl-4-vinyl-2H-1,2,3-triazole
• Synonyms: 2-phenyl-4-vinyl-2H-1,2,3-triazole
• CAS NO: 1339003-34-7
• Molecular Weight: 171.202
• Mol File: 1339003-34-7.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 2-phenyl-4-vinyl-2H-1,2,3-triazole(CAS DataBase Reference)
• NIST Chemistry Reference: 2-phenyl-4-vinyl-2H-1,2,3-triazole(1339003-34-7)
• EPA Substance Registry System: 2-phenyl-4-vinyl-2H-1,2,3-triazole(1339003-34-7)

Safety Data

• Hazardous Substances Data: 1339003-34-7(Hazardous Substances Data)

Upstream product

• 6341-06-6 2-phenyl-4-(D-arabino-1',2',3',4'-tetrahydroxybutyl)-2H-1,2,3-triazole 
• 534-97-4 glucosazone 
• 100-63-0 phenylhydrazine 
• 3213-80-7 2-phenyl-1,2,3-triazole-4-carboxaldehyde 
• 1779-49-3 Methyltriphenylphosphonium bromide 

Relevant articles and documents

1-Phenyl-1H- and 2-phenyl-2H-1,2,3-triazol derivatives: Design, synthesis and inhibitory effect on alpha-glycosidases

Due to aging and increasingly overweight in human population, the incidence of non-insulin dependent diabetes mellitus (NIDDM or Type 2 DM) is increasing considerably. Therefore, searching for new α-glycosidase inhibitors (GIs) capable of slowing down carbohydrate assimilation by humans is an important strategy towards control of NIDDM. In this report, we disclose the search for new easily accessible synthetic triazoles as anti-diabetic compounds. Two series of non-glycosid triazoles were synthesized (series A and B) and screened against baker's yeast α-glucosidase (MAL12) and porcine pancreatic α-amylase activity (PPA). Of the 60 compounds tested at 500 μM, were considered hits (≥60% inhibition) six triazoles against MAL12 and three against PPA, with the inhibition reaching up to 99.4% on MAL12 and 88.6% on PPA. The IC50 values were calculated for both enzymes and ranged from 54 to 482 μM for MAL12 and 145 to 282 μM for PPA. These results demonstrated the potential activity of simple and non-glycosidic triazoles as an important novel class of GIs for the development of drugs to treat Type 2 DM.